OMEROS CORP Additional Paid in Capital, Common Stock
OMEROS CORP (OMER) had Additional Paid in Capital, Common Stock of $724.24 million as of 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent › Additional Paid in Capital
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2024-11-13
- 2024-09-30: Additional Paid in Capital, Common Stock $724.24M.
- 2024-06-30: Additional Paid in Capital, Common Stock $721.58M.
- 2024-03-31: Additional Paid in Capital, Common Stock $718.81M.
- 2023-12-31: Additional Paid in Capital, Common Stock $727.94M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2024-09-30 | $724.24M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $721.58M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $718.81M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $727.94M 10-Q · filed 2024-11-13 |
| 2023-09-30 | $729.88M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $726.59M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $723.73M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $720.77M 10-K · filed 2024-04-01 |
| 2022-09-30 | $717.51M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $713.66M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $710.59M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $706.29M 10-K · filed 2023-03-13 |
| 2021-09-30 | $700.43M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $694.13M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $689.88M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $751.30M 10-K · filed 2022-03-01 |
| 2020-09-30 | $747.46M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $635.12M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $631.23M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $625.05M 10-K · filed 2021-03-01 |
| 2019-09-30 | $564.98M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $558.16M 10-Q · filed 2019-08-08 |
| 2018-12-31 | $549.48M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |